MeiraGTx(US:MGTX)2026-03-30 12:13Manufacturing and Facilities - The company operates two viral vector production facilities in London and Shannon, with a total capacity of 179,000 square feet, designed to meet GMP requirements for clinical and commercial production[26][27]. - The London facility was re-certified by the MHRA in Q2 2024, ensuring compliance with global regulatory standards[26]. - The London manufacturing facility spans 29,000 square feet and is designed to meet multiple regulatory standards, enabling the production of various product candidates in parallel[143]. - The Shannon facility, operational since 2022, encompasses 150,000 square feet and includes capabilities for viral vector production, plasmid DNA manufacturing, and advanced quality control testing[146]. - The manufacturing capabilities are expected to support both clinical and commercial production, ensuring sufficient capacity for future product approvals[147]. - The internal manufacturing capacity is expected to minimize dependence on third-party contract manufacturers, significantly reducing the cost of goods sold[149]. - Significant investment in internal manufacturing capacity provides better control over process development timelines, costs, product quality, and intellectual property[151]. - The company has over 190 highly trained multidisciplinary staff in manufacturing, quality, and supply teams to expedite gene therapy product delivery[148]. Financial Agreements and Collaborations - In December 2023, the company received a non-refundable upfront cash payment of $65 million from Johnson & Johnson Innovative Medicine as part of an asset purchase agreement[34]. - Future contingent consideration from Johnson & Johnson could total up to $350 million, including milestone payments for the initiation of clinical trials and commercial sales of the RPGR Product[34]. - The collaboration with Hologen Limited includes an upfront cash payment of $200 million and potential additional funding of up to $230 million for the development of gene therapies[35]. - The strategic collaboration with Hologen includes a Framework Agreement for the development and commercialization of gene therapies for Parkinson's disease and other conditions[37]. - The Lilly Collaboration Agreement includes an upfront payment of $75 million and potential milestone payments exceeding $400 million[46]. - Hologen has an exclusive option to purchase additional shares in MeiraGTx Manufacturing, potentially owning 40% of the issued share capital[43]. Clinical Development and Trials - The company has produced GMP clinical trial material for eight different indications using multiple AAV serotypes, demonstrating its manufacturing capabilities[29]. - The company aims to develop vectors for treating neurodegenerative diseases, starting with Parkinson's disease, which affects nearly 1 million Americans[65]. - AAV-GAD gene therapy demonstrated a significant decrease in UPDRS scores by 8.1 points (23.1%) in the treatment group compared to a 4.7 points (12.7%) decrease in the sham group at the six-month endpoint[67]. - The high dose AAV-GAD group showed an 18-point average improvement in UPDRS Part 3 "off" medication score at Week 26 (p=0.03), while no significant change was observed in the sham or low dose groups[72]. - The PDQ-39 score improved by 8 points (p=0.02) in the high dose group and by 6 points (p=0.04) in the low dose group, with 100% of high dose participants reporting improvement[75]. - AAV-GAD was well-tolerated with no significant adverse events related to the therapy reported during the trials[68]. - The Phase 1 bridging study for AAV-GAD included 14 subjects, with doses of 7.0×10^10 vg for low dose and 21×10^10 vg for high dose[71]. - AAV-hAQP1 for treating radiation-induced xerostomia has shown saliva flow increases of 60% to 540% in clinical trials[57]. - The FDA granted orphan drug designation and Breakthrough Therapy Designation to AAV-hAQP1 for treating grade 2 and 3 xerostomia[62]. - MeiraGTx is conducting IND-enabling studies for AAV-hAQP1 targeting xerostomia caused by Sjogren's syndrome[63]. - AAV-UPF1 is being developed to address motor neuron death in ALS, showing reduced motor neuron death in preclinical studies[78]. - AAV-AIPL1 has been manufactured for compassionate use to treat 11 children with LCA4, showing improved visual acuity and functional vision without serious adverse effects[92]. - The first cohort of 4 children treated with rAAV8.hRKp.AIPL1 showed a mean visual acuity improvement from 2.7 LogMAR to 0.9 LogMAR after a mean follow-up of 3.5 years[94]. - All 11 children treated with rAAV8.hRKp.AIPL1 have shown meaningful visual acuity responses, with improvements observed 4 or more weeks post-treatment[95]. - AAV-RPE65, developed for RPE65-associated retinal dystrophy, has an estimated prevalence of 6,000 patients across the U.S., Japan, and several European countries[102]. - AAV-CNGB3 and AAV-CNGA3 are designed to treat achromatopsia, with approximately 12,000 patients estimated in the U.S. and Europe, and about 125 new cases diagnosed annually[106]. - AAV-BBS10 has been manufactured for compassionate use under an MHRA specials license to treat BBS patients, with plans to use data for future clinical development[114]. - AAV-RDH12 received orphan drug designation and rare pediatric disease designation from the FDA for treating RDH12-associated retinal dystrophy[118]. - AAV-RetGC received rare pediatric disease designation from the FDA for treating LCA1 due to GUCY2D mutations in January 2025[119]. - The company is developing gene therapy candidates targeting wet AMD and dry AMD, including a partnership with ZipBio for AI-designed complement inhibitors[121]. - The company has a robust and diverse clinical and preclinical pipeline focusing on gene therapy for ocular disorders, salivary gland disorders, and neurodegenerative diseases[122]. Intellectual Property and Regulatory Matters - The company holds 530 issued or allowed patents and 351 pending patent applications as of December 31, 2025[157]. - The company owns ten patent families related to gene regulation platform technologies, with a total of 180 issued patents and 73 pending applications[159]. - The company has licensed patent families from UCLB, Brandeis University, and NIDCR, enhancing its intellectual property portfolio[171]. - The company anticipates facing intense competition as new drugs enter the market, impacting the commercialization of its treatments[155]. - The company sold rights to a patent family related to the RPGR Product to Johnson & Johnson Innovative Medicine on December 20, 2023[178]. - The company’s patent families related to gene therapy programs are expected to expire between 2033 and 2047, depending on jurisdictional patent term adjustments[177][180]. - The second patent family includes 18 pending applications across multiple jurisdictions, with patents expected to expire on August 4, 2042[183]. - Under the Third UCLB License Agreement, an initial upfront payment of £6,994 was made, along with £100,000 in ordinary shares issued to UCLB[185]. - Sales milestone payments of up to £39.8 million are required under the Stand-Alone UCLB Agreements, along with an annual management fee of £50,000 until certain royalty payments are made[187]. - An upfront payment of £1.5 million and £1.5 million in ordinary shares were paid to UCLB for the CNGB3-related Stand-Alone UCLB Agreement[187]. - Low single-digit percentage royalty payments on net sales of licensed products will commence upon the first commercial sale under each Stand-Alone UCLB Agreement[188]. - The Brandeis Agreement includes developmental and regulatory milestone payments of up to $1.0 million and annual license maintenance fees ranging from $15,000 to $100,000[194]. - The Brandeis Agreement mandates low single-digit percentage royalty payments on net sales of licensed products and mid-teen percentages of sublicensing revenues[194]. FDA Regulations and Compliance - The FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of a biological product[205]. - The FDA recommends observing subjects for potential gene therapy-related delayed adverse events for a 15-year period post-approval[205]. - The FDA requires extensive monitoring and auditing of clinical activities, with annual progress reports and IND safety reports to be submitted promptly[206]. - Phase 1 trials focus on safety in healthy subjects, while Phase 2 evaluates efficacy and safety in a limited patient population, and Phase 3 assesses overall risk/benefit in a larger group[208]. - The FDA aims to complete the review of standard BLAs within ten months and priority reviews within six months after acceptance for filing[215]. - A complete response letter may be issued by the FDA if the BLA does not meet regulatory criteria, detailing specific deficiencies that need to be addressed[218]. - Orphan drug designation can provide financial incentives, including grant funding and user-fee waivers, and grants exclusivity for seven years under certain conditions[223]. - The FDA's Fast Track program expedites the review process for candidates addressing serious conditions and unmet medical needs, allowing for more frequent interactions with the review team[224]. - The manufacturing process must comply with cGMP requirements to ensure consistent production and quality of the biological product candidate[210]. - The FDA may require post-market studies to monitor safety and effectiveness after commercialization, which can affect further marketing of the product[221]. - The sponsor must submit a Pediatric Study Plan within sixty days after an end-of-Phase 2 meeting for products with new indications or active ingredients[212]. - The FDA may withdraw product approval if compliance with pre- and post-marketing requirements is not maintained[220]. Technology and Innovation - The company has developed a proprietary riboswitch platform that allows for precise control of gene expression via orally delivered small molecules, enhancing the delivery of biologic therapeutics[30]. - The proprietary riboswitch technology platform allows for precise, dose-responsive control of gene expression, potentially transforming gene therapy applications[130]. - The riboswitch platform enables the expression of any mRNA and protein via oral dosing, opening new therapeutic targets in metabolism[141]. - The company aims to advance its first riboswitch program for metabolic disease, targeting leptin deficiency with a one-time intramuscular delivery system[137]. - Over 40 gene therapies have received regulatory approval in recent years, indicating a growing acceptance of gene therapy technology[123]. - The company has established relationships with leading institutions to enhance development strategies and facilitate patient enrollment for clinical trials[122]. - The company is pursuing strategic collaborations with biotechnology and pharmaceutical companies to leverage its capabilities and technology[126].